Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC

Clinical Trial ID NCT03672305

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03672305

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982 43.81
2 B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2011 8.26
3 Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011 7.49
4 Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011 7.09
5 Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014 5.60
6 Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014 2.84
7 Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014 2.63
8 Treating cancer with genetically engineered T cells. Trends Biotechnol 2011 1.83
9 Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 2014 1.64
10 Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis 2015 1.51
11 Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther 2009 1.44
12 Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016 1.07
13 Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends Mol Med 2015 0.96
14 Combinatorial immunotherapy strategies for hepatocellular carcinoma. Curr Opin Immunol 2016 0.81
15 Chimeric antigen receptor T-cell therapy to target hematologic malignancies. Cancer Res 2014 0.80
16 Hepatocellular carcinoma and hepatitis B surface protein. World J Gastroenterol 2016 0.79
Next 100